The OMX Copenhagen 20 index surged over 6%, driven by Novo Nordisk's 12% jump after Eli Lilly's weight-loss drug trial results disappointed, causing Lilly's shares to drop 12.9%. N...
Novo Nordisk shares fell 8% after Eli Lilly reported positive trial results for its weight loss drug, orforglipron, affecting the healthcare sector. Novo Nordisk's shares dropped t...
Novo Nordisk shares fell 8% after Eli Lilly revealed positive trial results for its weight loss drug orforglipron, impacting the healthcare sector. Eli Lilly's shares saw a slight ...
Novo Nordisk shares fell 8% after Eli Lilly announced positive trial results for its weight loss drug orforglipron, impacting the healthcare sector. Eli Lilly's stock rose slightly...
Novo Nordisk shares fell 8% after Eli Lilly announced positive trial results for its weight loss drug, orforglipron, impacting the healthcare sector. Novo Nordisk's shares dropped ...
Novo Nordisk shares fell 8% after Eli Lilly announced positive results from a late-stage trial of its oral weight loss drug, orforglipron, impacting the healthcare sector broadly.
Novo Nordisk shares fell 8% after Eli Lilly announced positive late-stage trial results for its oral weight loss drug, orforglipron, impacting the healthcare sector and Novo Nordis...
